XL228 is a multi-targeted tyrosine kinase inhibitor with IC 50 s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl , Aurora A , IGF-1R , Src and Lyn , respectively.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pain | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Cancer | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Endocrinology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Aurora Kinase | Products > Signaling Pathways > Bcr-Abl | Products > Signaling Pathways > IGF-1R | Products > Signaling Pathways > Src
感谢您来到爆牛贸易,请为我们留言或者使用以下方式联系我们,我们将尽快给您回复,并为您提供最真诚的服务,谢谢。